BioAlliance Pharma appoints Nicolas Fellmann as CFO

BioAlliance Pharma SA, an emerging specialty pharmaceutical company, has announced the appointment of Nicolas Fellmann as Chief Financial Officer. Fellmann will play a key role in the growth of the company.

A graduate of the Lyon School of Management, Fellmann, 38, has more than 10 years experience in the pharmaceutical industry. His previous posts were as Director, treasury, tax and audit in the finance department of Pfizer France. He started his career with Ernst & Young, leaving in 1995 as Senior Financial Auditor.

“The arrival of Nicolas Fellmann marks a new turning point for BioAlliance Pharma,” said Dominique Costantini, MD, President and CEO of BioAlliance Pharma. “His experience of the pharmaceutical industry and his management abilities will be important assets as we address the challenges of fast growth and the launch and production of our medicines.”

The new CFO joins BioAlliance just after the company obtained a Marketing Authorization in France for its first product, Loramyc, a treatment for oropharyngeal candidiasis in immuno-depressed patients. BioAlliance is already making preparations for the launch of this product, planned for early 2007. The company is continuing to move forward with its other research programs. Acyclovir Lauriad® and doxorubicin Transdrug are being prepared for Phase II/III clinical trials.